Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05924074
NA

Ferroptosis Study in SF3B1-mutant Myelodysplastic Syndromes (FerMDS)

Sponsor: University Hospital, Bordeaux

View on ClinicalTrials.gov

Summary

Myelodysplastic syndromes (MDS) are clonal diseases of hematopoietic stem cells (HSC) characterized by dysplastic and inefficient hematopoiesis related to excessive progenitor cell death. Ferroptosis is a recently described cell death mechanism and we think that it could be a major player in the pathophysiology of MDS, involved in the cell death that characterizes these diseases and contributing to cytopenias. The study aims to demonstrate that there is a significant activation of this phenomenon in MDS patients compared to a population of subjects without MDS.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

80

Start Date

2025-02-21

Completion Date

2027-02

Last Updated

2025-03-19

Healthy Volunteers

No

Interventions

BIOLOGICAL

Biological sampling

The procedure will consist of an additional bone marrow sample and blood sample

Locations (3)

CHU de Bordeaux, Laboratoire d'Hématologie

Pessac, France

CHU de Bordeaux, Service de Médecine Interne

Pessac, France

CHU de Bordeaux, Service Hématologie Clinique et Thérapie Cellulaire

Pessac, France